Glenmark starts phase-3 clinical trials on Favipiravir for covid patients in India
The trial completion and study results are expected by July-August this year. Glenmark was the first pharmaceutical company in India to be given an approval by the regulator to conduct Phase 3 clinical trials in India on Favipiravir antiviral tablets for COVID -19 patients.
Glenmark Pharmaceuticals said on Tuesday that it has initiated phase - three clinical trials on antiviral Favipiravir for COVID-19 patients in India, Photo: Reuters